7 Nov 2019 12:45
Â
Â
Â
Ovoca Bio plc
("Ovoca" or the "Company")
Â
Attendance at BIO-Europe Conference
Â
Dublin, Ireland, November 7, 2019 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, today announces that the Company will be attending the 25th annual BIO-Europe Partnering Conference, taking place from 11-13 November 2019, in Hamburg, Germany.
Â
Management will host one-on-one meetings with investors at the Conference. To inquire about arranging a meeting with management, please contact Dr Daniel Nemenov, at Ovoca Bio.
Â
Â
Â
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Â
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
Â
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.
Â
The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Â
Ovoca Bio has filed for approval for the marketing of BP-101 in Russia and is seeking to develop the drug for major global markets - in particular the United States and Europe.
Â